DelMar Pharmaceuticals Announces Accelerated Patient Enrollment of Phase 2 Trial in MGMT-unmethylated Recurrent GBM Jun 26, 2018
DelMar Pharmaceuticals Appoints World-Renowned Molecular Biologist Dr. Napoleone Ferrara to Board of Directors Jun 25, 2018
DelMar Pharmaceuticals Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM Apr 17, 2018
DelMar Pharmaceuticals Announces Multiple Presentations at Annual Meeting of the American Association for Cancer Research Apr 16, 2018
